List of Excipients in Branded Drug MYXREDLIN

MYXREDLIN Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

MYXREDLIN is a ready-to-use intravenous human insulin product containing 1 unit/mL insulin human in a 100 mL sodium chloride presentation. Its commercial value is linked to preparation efficiency, dosing consistency, and reduced pharmacy compounding rather than a novel insulin molecule. The main excipient opportunities involve insulin stabilization, adsorption control, container compatibility, preservative management, and differentiated ready-to-administer presentations.

What is MYXREDLIN and how is it formulated?

MYXREDLIN is an intravenous infusion product approved for glycemic control in adults and pediatric patients requiring treatment with insulin. Baxter Healthcare Corporation markets the product under FDA-approved NDA 208313.[1]

Attribute	MYXREDLIN
Active ingredient	Insulin human
Concentration	1 unit/mL
Presentation	100 units in 100 mL
Route	Intravenous infusion
Diluent	0.9% sodium chloride
Dosage form	Ready-to-use infusion solution
Primary setting	Hospital and acute-care use
FDA application	NDA 208313
Product type	Recombinant human insulin biologic
Commercial differentiator	Premixed, ready-to-administer IV insulin

The formulation contains insulin human, sodium chloride, glycerin, m-cresol, polysorbate 20, and water for injection. The label identifies m-cresol as a preservative and includes excipients that support product stability and solution performance.[1]

MYXREDLIN is supplied in a standard 100 mL container. The 1 unit/mL concentration simplifies dose calculations because the numerical infusion rate in mL/hour corresponds directly to insulin units/hour.

What excipients are used in MYXREDLIN?

The principal excipient system includes glycerin, m-cresol, polysorbate 20, sodium chloride, and water for injection.

Excipient	Functional role	Commercial relevance
Glycerin	Tonicity adjustment and solution stabilization	Supports isotonicity and may reduce protein-interface stress
M-cresol	Antimicrobial preservative	Helps maintain multidose or in-use microbiological control
Polysorbate 20	Surfactant	Limits adsorption and interfacial aggregation of insulin
Sodium chloride	Tonicity and vehicle component	Aligns the formulation with standard saline infusion practice
Water for injection	Solvent	Parenteral-grade aqueous vehicle

Insulin is susceptible to adsorption onto glass, plastic, tubing, filters, and other infusion-system surfaces. Surfactants such as polysorbate 20 can reduce surface losses, while protein-stabilizing excipients can limit aggregation during storage and administration. The formulation must maintain potency through the labeled storage period and during the infusion process.

The formulation strategy is therefore functional rather than cosmetic. Each excipient must support one or more critical quality attributes: potency, purity, clarity, particulate control, sterility, preservative performance, osmolality, pH, and compatibility with the infusion container and administration set.

How does MYXREDLIN compare with compounded IV insulin?

MYXREDLIN competes primarily with hospital-prepared insulin infusions rather than with subcutaneous insulin products.

Commercial factor	MYXREDLIN	Pharmacy-compounded IV insulin
Preparation	Ready to use	Requires dilution and verification
Concentration	Standardized at 1 unit/mL	May vary by protocol
Pharmacy labor	Lower	Higher
Dose-calculation risk	Lower	Higher
Inventory flexibility	Lower	Higher
Custom concentration	Generally unavailable	Possible
Waste risk	Depends on patient volume and shelf life	Depends on batch size
Regulatory control	Manufacturer-controlled	Institution-controlled
Administration workflow	Standardized	Site-specific

The strongest commercial case is in intensive care units, emergency departments, operating rooms, neonatal and pediatric units, and other settings in which rapid insulin initiation and frequent titration create recurring compounding demand.

A ready-to-use presentation can reduce pharmacy preparation, labeling, independent-check requirements, and variability in final concentration. These advantages can support hospital formulary placement even when the acquisition price exceeds the cost of insulin vials and saline.

What excipient strategies could expand MYXREDLIN’s commercial opportunity?

1. Improve protein adsorption control

The most direct technical opportunity is to optimize the surfactant system. Polysorbate 20 is already used in MYXREDLIN, but alternative strategies could include:

• Polysorbate 80, subject to compatibility and impurity control.
• Poloxamers or other nonionic surfactants.
• Low-adsorption container and tubing materials.
• Silicone-oil and stopper compatibility controls.
• Surface-treatment approaches for infusion-contact components.

A new formulation would need to demonstrate equivalent or superior insulin recovery after contact with infusion bags, administration sets, filters, and common hospital devices. A formulation that maintains delivered potency across more administration systems could support a device-linked or compatibility-based product claim.

2. Reduce preservative burden

M-cresol contributes antimicrobial protection but can create tolerability, compatibility, and preservative-exposure considerations. A preservative-free single-use presentation could target institutions seeking simplified excipient profiles or reduced exposure to phenolic preservatives.

The principal tradeoff is microbiological risk. A preservative-free product would require a tightly controlled single-use container, validated aseptic processing, and clear in-use limits. It could be commercially attractive if positioned for pediatric, neonatal, or highly controlled critical-care use.

3. Develop longer in-use stability

Hospitals need infusion products that remain stable during extended administration and storage after removal from refrigeration. A formulation with validated room-temperature stability, low adsorption, and extended in-use performance could reduce waste and improve inventory management.

The relevant data package would include:

• Insulin potency over the proposed use period.
• High-molecular-weight protein formation.
• Subvisible and visible particles.
• pH and osmolality.
• Preservative concentration.
• Container-closure integrity.
• Compatibility with infusion tubing and filters.
• Stability under light and temperature excursions.

A longer in-use claim would have direct purchasing value because it could reduce discarded product during low-volume periods.

4. Create pediatric and neonatal presentations

The standard 100 mL format may be inefficient for neonates and small children, where fluid volume is clinically important. Potential presentations include:

• 25 mL or 50 mL ready-to-use bags.
• Higher-concentration products that reduce fluid load.
• Syringe-based presentations for controlled infusion.
• Low-sorbing extension sets supplied with the product.
• Preservative-free single-patient-use formats.

Higher concentration introduces dosing-error and pump-programming risks. A commercially viable product would require prominent labeling, dedicated administration protocols, and human-factors validation.

5. Improve container and administration-set compatibility

An excipient strategy can be combined with packaging innovation. Insulin loss can occur through adsorption to the infusion pathway, particularly when a new set is primed or when low doses are delivered over time. A product supplied with validated low-binding tubing or a preconditioned administration set could differentiate on delivered-dose reliability.

This approach would create a combination-product or device-linked regulatory pathway if the administration component is necessary for the product’s intended performance. The opportunity is technically defensible but would increase development, manufacturing, and postmarket obligations.

What formulation patents could protect a MYXREDLIN follow-on?

A follow-on formulation would require claims that distinguish it from the known insulin-in-saline composition and standard hospital compounding practice. Potential claim categories include:

1. A specific insulin concentration and excipient combination.
2. A defined polysorbate or surfactant concentration range.
3. A low-adsorption formulation for a specified container and tubing system.
4. A preservative-free IV insulin formulation with defined in-use stability.
5. A concentrated insulin infusion formulation with reduced fluid volume.
6. A container-closure system that maintains insulin recovery.
7. A ready-to-administer bag with validated administration-set compatibility.
8. A formulation with reduced aggregation after agitation, temperature cycling, or prolonged infusion.

The strongest claims would link composition to measurable performance. Broad claims covering insulin in saline are vulnerable to prior-art challenges because insulin infusion solutions and adsorption-control methods are established technologies. Narrow claims supported by comparative recovery, stability, and clinical workflow data would have greater defensibility.

Patent applicants should consider composition-of-matter claims, formulation claims, container-system claims, process claims, and method-of-use claims. Trade-secret protection may be more effective for certain manufacturing parameters, including surfactant addition order, mixing conditions, filtration, hold times, and filling operations.

What is the FDA regulatory status of MYXREDLIN?

MYXREDLIN is an FDA-approved insulin human injection product under NDA 208313.[1] It is regulated as a biologic drug product because insulin is a protein therapeutic. FDA’s insulin transition framework moved insulin products from the Federal Food, Drug, and Cosmetic Act drug framework into the Public Health Service Act biologics framework in 2020.[2]

A competing human insulin product may pursue:

• A full 351(a) biologics license application.
• A 351(k) biosimilar pathway where the product and reference-product requirements are satisfied.
• An abbreviated pathway where applicable to the specific product and regulatory context.

The practical development burden includes analytical comparability, manufacturing controls, sterility assurance, container compatibility, stability, and clinical or pharmacodynamic evidence appropriate to the proposed pathway. An excipient change can prevent a product from qualifying as a simple interchangeable substitute if it materially affects safety, delivery, or administration.

What is the Orange Book and patent status of MYXREDLIN?

MYXREDLIN is a biologic insulin product, so its principal exclusivity and patent analysis should be conducted through FDA biologics records, the Purple Book framework, FDA application materials, and public patent databases rather than assuming a conventional small-molecule Orange Book profile.[3]

The product’s commercial protection is likely driven more by manufacturing know-how, hospital contracts, regulatory approval, trademarks, and formulation or packaging patents than by a conventional active-ingredient patent. No patent expiration date should be assigned without a verified patent number, claim scope, ownership chain, and terminal-disclaimer analysis.

Paragraph IV certification is a Hatch-Waxman mechanism associated primarily with abbreviated new drug applications. It is not the normal legal framework for a follow-on insulin biologic seeking approval through the 351(k) pathway. A competitor could still challenge patents through federal litigation or declaratory-judgment actions, depending on the product’s regulatory route and applicable patent-dispute procedures.

When does MYXREDLIN lose exclusivity?

MYXREDLIN’s commercial exclusivity cannot be determined from the approval date alone. Relevant protections may include regulatory exclusivity, patents, pediatric exclusivity, trademarks, manufacturing controls, and contracts.

Protection category	Relevance to MYXREDLIN
Patent exclusivity	Depends on identified formulation, packaging, process, or use patents
Regulatory exclusivity	Depends on the applicable biologic approval framework
Pediatric exclusivity	Requires verification in FDA records
Trademark protection	Protects the MYXREDLIN brand, not the active ingredient
Trade secrets	May protect manufacturing and quality-control processes
Hospital contracts	May delay formulary substitution without blocking approval

The first commercially credible competitor could enter through a differentiated ready-to-use insulin product rather than a direct copy. A lower-cost premix, a smaller-volume pediatric bag, or a preservative-free product could avoid direct price competition while targeting separate hospital protocols.

Which companies could challenge MYXREDLIN commercially?

The competitive field includes insulin manufacturers, hospital compounding pharmacies, contract manufacturers, and suppliers of ready-to-administer sterile products. Potential competitors include companies with:

• Recombinant human insulin manufacturing capacity.
• Sterile liquid filling and bag technology.
• Hospital distribution infrastructure.
• 351(k) biologic development capability.
• Existing ICU and critical-care formulary access.

The strongest competitive threat is likely from a manufacturer that combines insulin supply with ready-to-administer packaging, validated tubing compatibility, and a hospital purchasing program. A low-cost vial alone would not necessarily replicate MYXREDLIN’s workflow value.

What licensing opportunities exist for MYXREDLIN excipients?

Licensing targets may include:

• Low-binding infusion bag technologies.
• Protein-stabilizing surfactant systems.
• Preservative-free sterile filling platforms.
• Extended-stability excipient packages.
• Pediatric low-volume delivery systems.
• Smart infusion-device compatibility.
• Contract manufacturing for premixed biologic solutions.

A license should be evaluated against freedom-to-operate risk covering surfactants, container materials, sterilization, filling, and administration sets. The commercial value increases when the licensed technology produces a measurable hospital benefit, such as reduced insulin loss, lower nursing preparation time, fewer pharmacy interventions, or reduced product waste.

What generic launch risks exist for MYXREDLIN?

The principal launch risks are:

1. Demonstrating equivalent delivered insulin potency after infusion-system contact.
2. Establishing stability in the intended container.
3. Managing biologic aggregation and particulate formation.
4. Reproducing the product’s concentration accurately at commercial scale.
5. Securing hospital contracts against an established ready-to-use product.
6. Avoiding dosing confusion between 1 unit/mL and concentrated presentations.
7. Establishing a legally viable patent and regulatory pathway.
8. Meeting sterile manufacturing and supply-continuity requirements.

A successful entrant should compete on total treatment cost rather than acquisition price alone. Pharmacy labor, preparation errors, discarded product, nursing time, and inventory requirements are central components of the economic case.

Key Takeaways

• MYXREDLIN is a ready-to-use 1 unit/mL IV human insulin product in a 100 mL sodium chloride presentation.
• Its excipient system includes glycerin, m-cresol, polysorbate 20, sodium chloride, and water for injection.
• The most valuable formulation opportunities involve adsorption control, preservative reduction, extended in-use stability, pediatric volume reduction, and container compatibility.
• A follow-on product should pursue narrow, performance-supported formulation and packaging claims.
• Insulin follow-on competition is primarily a biologics and hospital-product issue, not a conventional small-molecule Paragraph IV strategy.
• The strongest commercial differentiation is likely to come from workflow savings, validated administration performance, and specialized pediatric or critical-care presentations.
• Patent and exclusivity conclusions require verified FDA and public patent records; the approval date alone does not establish a MYXREDLIN loss-of-exclusivity date.

FAQs About MYXREDLIN Excipients and Commercial Strategy

Is MYXREDLIN premixed with normal saline?

Yes. MYXREDLIN contains 1 unit/mL insulin human in 0.9% sodium chloride and is supplied as a ready-to-use intravenous infusion product.[1]

Does MYXREDLIN contain polysorbate 20?

Yes. Polysorbate 20 is included as a formulation surfactant to help control insulin adsorption and interfacial instability.[1]

Could a preservative-free MYXREDLIN competitor be commercially attractive?

Yes. A preservative-free product could target neonatal, pediatric, or single-patient-use settings, but it would require strong aseptic-processing, container-closure, and in-use stability data.

Is MYXREDLIN interchangeable with all IV insulin preparations?

No. Concentration, excipients, container, administration set, labeling, and approved instructions must be evaluated before substitution. Hospital protocols should not assume automatic interchangeability.

What is the strongest patent angle for a MYXREDLIN follow-on?

A narrow claim tied to demonstrated low adsorption, extended stability, specialized packaging, or reduced-volume pediatric delivery is likely stronger than a broad claim covering insulin in saline.

References

1. U.S. Food and Drug Administration. (n.d.). MYXREDLIN (insulin human) injection, solution: Prescribing information. NDA 208313. Baxter Healthcare Corporation.

2. U.S. Food and Drug Administration. (2020). Insulin products and the transition from the Federal Food, Drug, and Cosmetic Act to the Public Health Service Act. https://www.fda.gov

3. U.S. Food and Drug Administration. (n.d.). Purple Book: Database of licensed biological products. https://purplebooksearch.fda.gov